As the PR says they are about to start a pivotal clinical trial, is it fair to assume that either they have done the P1 / BE study already (unlikely) or the BE study will be built into the Pivotal trial itself.
I wonder how BE is done for intravitreal injectable products?
And by the time, biosimilars reach to market, they may have switched most patients to log acting version.
Market Data 
Markets 
AI
